FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesLeadership Lessons for Re-Entry
Topics: Leadership, Management
Webinar
Free
2024 US Conference – Sponsorship and Exhibitor Overview
Topic: Conference
Presentation
Free
GDPR Considerations for DtP Supply Chains
Topics: Regulatory, Supply Chain
Guidance Document
Free
